WhaleCreep

Fairmount Funds Management LLC 13F holdings, Q1 2025

Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →

Fairmount Funds Management LLC disclosed 15 US equity positions worth $644.6m in its Q1 2025 13F filing. The largest position was AXSM at 14.7% of the reported book, followed by APGE and SYRE. Against the Q4 2024 filing, it opened 0 new positions, added to 0 and reduced 5 among the top 15 holdings.

← Q4 2024 · Q2 2025 →

What did Fairmount Funds Management LLC own in Q1 2025? Top 15 positions

#StockSectorWeightValueSharesΔ sharesvs Q4 2024
1 AXSM AXSOME THERAPEUTICS INC Healthcare 14.7%$95.1m815,176 -45% reduced
2 APGE APOGEE THERAPEUTICS INC Healthcare 11.9%$76.5m2,048,647 0% held
3 SYRE SPYRE THERAPEUTICS INC 10.1%$64.8m4,018,101 0% held
4 ELVN ENLIVEN THERAPEUTICS INC Healthcare 9.8%$63.0m3,202,798 0% held
5 NUVALENT INC 8.0%$51.6m727,563 -45% reduced
6 DNTH DIANTHUS THERAPEUTICS INC Healthcare 7.6%$49.0m2,700,691 0% held
7 VRDN VIRIDIAN THERAPEUTICS INC Healthcare 7.2%$46.4m3,445,813 0% held
8 SRRK SCHOLAR ROCK HLDG CORP Healthcare 6.9%$44.2m1,374,031 -30% reduced
9 COGT COGENT BIOSCIENCES INC Healthcare 5.8%$37.3m6,225,641 0% held
10 ORKA ORUKA THERAPEUTICS INC Healthcare 5.4%$34.6m3,371,922 0% held
11 KINIKSA PHARMACEUTICALS INTL 3.8%$24.5m1,102,248 -50% reduced
12 CATBUSD ASTRIA THERAPEUTICS INC 2.9%$19.0m3,554,129 0% held
13 ZBIO ZENAS BIOPHARMA INC 2.3%$15.0m1,892,806 0% held
14 IKT INHIBIKASE THERAPEUTICS INC 2.1%$13.4m6,125,000 0% held
15 BCAX BICARA THERAPEUTICS INC 1.6%$10.2m784,170 -39% reduced

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.